follicular carcinoma with clinical phenotype of "hot nodule"
*based on 50 hot nodules investigated by Paschke et al. 1994, Parma et al. 1997, Duprez et al. 1997, Russo et al. 1996, Holzapfel et al. 1997, Porcellini et al. 1994, Tonacchera et al. 1998, Fuhrer et al. 1997, Tassi et al. 1999, Derwahl et al. 1996, Tonacchera et al. 1998 and 2000, Georgopoulos et al. 2003, Gozu et al. 2005 and 2006, Trulzsch et al. 2001, Palos-Paz et al. 2008, Sancak et al. 2011, Nishihara et al. 2009
and on 1 activating sporadic germline mutation investigated by Kopp et a. 1997
and on 2 hot thyroid carcinoma investigated by Spambalg et al. 1996 and
cAMP (basal): basal in vitro cAMP production of mutant over wild-type TSHR
cAMP (TSH): maximal in vitro cAMP production of mutant over wild-type TSHR
IP (basal): basal in vitro IP production of mutant over wild-type TSHR
IP (TSH): maximal in vitro IP production of mutant over wild-type TSHR
TSH-binding: maximal TSH-binding compared to the wild-type TSHR
Cell surface expression: cell surface expression of mutant compared to WT-TSHR
LRA: linear regression analysis (LRA) of constitutive activity as a function of TSHR expression determined by 125I-bTSH binding or FACS analysis compared to the wild-type TSHR
Prevalence: Prevalence of (somatic and germline) activating mutations*
Ref: Reference for functional characterization
Child: Found in children.